Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Phase 2 Study of SAR439859 Versus Physician's Choice in Premenopausal and Postmenopausal Locally Advanced or Metastatic ER-positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04059484
Recruitment Status : Recruiting
First Posted : August 16, 2019
Last Update Posted : December 11, 2019
Sponsor:
Information provided by (Responsible Party):
Sanofi

Brief Summary:

Primary Objective:

To determine whether SAR439859 per os improves progression free survival (PFS) when compared with an endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer.

Secondary Objectives:

  • To compare the objective response rate in the 2 treatment arms.
  • To evaluate the disease control rate in the 2 treatment arms.
  • To evaluate the clinical benefit rate in the 2 treatment arms.
  • To evaluate the duration of response in the 2 treatment arms.
  • To evaluate the PFS according to the estrogen receptor 1 gene (ESR1) mutation status in the 2 treatment arms.
  • To evaluate the overall survival in the 2 treatment arms.
  • To evaluate the pharmacokinetics of SAR439859 as single agent.
  • To evaluate health related quality of life in the 2 treatment arms.
  • To evaluate the overall safety profile in the 2 treatment arms.

Condition or disease Intervention/treatment Phase
Breast Cancer Metastatic Drug: SAR439859 Drug: Endocrine monotherapy as per physician choice Phase 2

Detailed Description:
The duration of the study for an individual participant will include a period to assess eligibility (screening period) of up to 4 weeks (28 days), a treatment period of at least 1 cycle (28 days of study treatment), and an end of treatment (EOT) visit at least 30 days (or until the participant receive another anticancer therapy, whichever is earlier) following the last administration of study treatment. Study treatment may continue until precluded by unacceptable toxicity, disease progression, death or upon participant's request.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 282 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as Per Physician's Choice in Premenopausal and Postmenopausal Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies
Actual Study Start Date : October 22, 2019
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : August 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: SAR439859
Daily SAR439859 dose administered orally
Drug: SAR439859
Pharmaceutical form:Capsule Route of administration: Oral

Active Comparator: Control treatment
Endocrine monotherapy as per physician choice
Drug: Endocrine monotherapy as per physician choice

Pharmaceutical form:

Route of administration:





Primary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: Up to 17 months after the first randomized participant ]
    PFS is defined as the time interval from the date of randomization to the date of documented tumor progression as per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or death (due to any cause), whichever comes first.


Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Up to 17 months after the first randomized participant ]
    ORR is defined as the proportion of participants who have a confirmed complete response (CR) or partial response (PR), as best overall response determined by RECIST 1.1 from the date of randomization to the date of end of treatment.

  2. Disease Control Rate (DCR) [ Time Frame: Up to 17 months after the first randomized participant ]
    DCR is defined as the proportion of participants who have a confirmed CR, PR, or stable disease (SD) determined by RECIST 1.1 from the date of randomization to the date of end of treatment.

  3. Clinical Benefit Rate (CBR) [ Time Frame: Up to 17 months after the first randomized participant ]
    CBR is defined as the proportion of participants who have a confirmed CR, PR, or stable disease (SD) for at least 24 weeks determined by RECIST 1.1 from the date of randomization to the date of end of treatment.

  4. Duration of Response (DOR) [ Time Frame: Up to 17 months after the first randomized participant ]
    DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) as determined by objective radiographic disease assessment per RECIST 1.1 or death from any cause, whichever occurs first.

  5. PFS according to (ESR1) mutation status [ Time Frame: Up to 17 months after the first randomized participant ]
    PFS as per the estrogen receptor 1 (ESR1) mutation status determined at study entry.

  6. Overall Survival (OS) [ Time Frame: Up to 35 months after the first randomized participant ]
    OS is defined as the time interval from the date of randomization to the date of documented death (due to any cause).

  7. Assessments of the Pharmacokinetic (PK) parameter of SAR439859: Plasma Concentrations [ Time Frame: Day 1 and Day 15 of Cycle 1 and Day 1 of subsequent cycle every 2 cycles upto to 30 days after last study treatment (each cycle is 28 days) ]
    SAR439859 plasma concentrations.

  8. Patient Reported Outcome (PRO) - health-related quality of life and health status using the European Quality of Life-5 Dimensions (EQ-5D) [ Time Frame: Day 1 of Cycle 1 and day 1 of subsequent cycle every 2 cycles up to to 30 days after last study treatment (each cycle is 28 days) ]
    EQ-5D is a standardized measure of health status.

  9. Patient Reported Outcome (PRO) - the European Organisation for Research and Treatment of Cancer core quality of life questionnaire (EORTC-QLQ-C30) [ Time Frame: Day 1 of Cycle 1 and day 1 of subsequent cycle every 2 cycles up to to 30 days after last study treatment (each cycle is 28 days) ]
    The EORTC-QLQ-C30 is composed of both multi item scales and single item measures. These include 5 functional scales, 3 symptom scales, a Global Health Status (GHS)/quality of life scale, and 6 single items.

  10. Patient Reported Outcome (PRO) - EORTC-QLQ breast cancer (EORTC-QLQ-BR23) [ Time Frame: Day 1 of Cycle 1 and day 1 of subsequent cycle every 2 cycles up to to 30 days after last study treatment (each cycle is 28 days) ]
    The EORTC-QLQ-BR23 contains 23 items: 8 assessing function and 15 items assessing symptoms of disease or treatment.

  11. Overall safety profile - Treatment-Emergent Adverse events [ Time Frame: Evaluated continuously throughout study from the date of enrollment, up to 30 days after last study treatment administration ]
    Number of participants with treatment-emergent adverse events (TEAEs).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria :

  • 18 years or older
  • Histological or cytological diagnosis of adenocarcinoma of the breast.
  • Locally advanced not amenable to radiation therapy or surgery in a curative intent, and/or metastatic disease.
  • ER positive status
  • HER2 negative status
  • For patients with tumor accessible for paired biopsy at study entry: baseline samples, formalin fixed paraffin embedded (FFPE) archived biopsy samples (within 3 months prior initiation of study treatment) can be used, but preferably fresh biopsies from primary tumor or recurrence or metastasis, will be collected.
  • Participants must have received no more than 1 prior chemotherapeutic or 1 targeted therapy regimen for advanced/metastatic disease.

Participants must have progressed after at least 6 months of a continuous prior endocrine therapy for advanced breast cancer

- Participants must be postmenopausal women

Exclusion criteria:

  • Eastern Cooperative Oncology Group performance status ≥2.
  • Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of SAR439859. Participants unable to swallow normally and to take capsules.
  • Participant with any other cancer. Adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or any other cancer from which the participant has been disease free for >3 years are allowed.
  • Severe uncontrolled systemic disease at screening
  • Participants with bone-only metastasis .
  • Participants with known brain metastases that are untreated, symptomatic or require therapy to control symptoms.
  • Prior treatment with mammalian target of rapamycin inhibitors or any other selective estrogen receptor degrader (SERD) compound, except fulvestrant if stopped for at least 3 months before randomization.
  • Treatment with antiviral agents, antifungal, and antioxidant agents less than 2 weeks before randomization .
  • Treatment with strong or moderate CYP3A inducers within 2 weeks before randomization.
  • Ongoing treatment with drugs that are substrate of P-glycoprotein (P-gp) (dabigatran, digoxin, fexofenadine).
  • Treatment with anticancer agents (including investigational drugs) less than 3 weeks before randomization.
  • Inadequate hematological, coagulation, renal and liver functions.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04059484


Contacts
Layout table for location contacts
Contact: Trial Transparency email recommended (Toll free number for US & Canada) 800-633-1610 ext 1 then # Contact-US@sanofi.com

Locations
Show Show 27 study locations
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi

Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT04059484    
Other Study ID Numbers: ACT16105
2018-004593-98 ( EudraCT Number )
U1111-1217-2774 ( Other Identifier: UTN )
First Posted: August 16, 2019    Key Record Dates
Last Update Posted: December 11, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases